Kornimate/medical-research-clean huggingface dataset:
does local cooling of testis in patients with epididymitis relieve pain and reduce quantity of analgetics intake?

Conditions: Pain

Summary: the investigators propose to examine the effect of local cooling of testis in participants with acute epididymitis or orchiepididymitis on participants reported pain level and analgetics consumption.

epididymitis or orchiepididymitis is an acute disease causing pain and discomfort. our hypothesis is that local cooling of the affected testis or epididymis may relieve the pain and reduce the analgetics consumption in order to examine this hypothesis we will recruit adult patients with epididymitis or orchiepididymitis and will randomize these patients to two arms. one arm will receive every 8 hours a brick cooled for at least 2 hours in -20(celsius) for local use on the affected hemiscrotum, while the second arm will receive a brick in room temperature. pain level will be estimated one hour following the application of the brick using visual analogue pain score. patient will receive analgetics according to a predefined escalating protocol. pain level and analgetics consumption will be compared between the two arms.

Eligibility criteria:
inclusion criteria: * male patients 18-99 years * acute epididymitis or acute orchiepididymitis exclusion criteria: * patient unable to informed consent * suspicion of testicular malignancy
clopidogrel response in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: the aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (clr) in the acute phase after an ischemic stroke.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke * admittance to stroke unit * clopidogrel medication exclusion criteria: * no consent * prior bleeding disorders * severe liver disorders * current gastrointestinal disorders * congestive heart failure * life-threatening malignancies

Keywords: stroke clopidogrel aggregometry antiplatelet therapy platelet function tests
efficacy of patient centred information for vascular disease

Conditions: Vascular Disease

Summary: this study aims to determine the usefulness of providing patients with web-based electronically accessed patient information when compared to the provision of written information leaflets.

hospitals and health care institutions attempt to provide information to patients through a variety of media including; written information, web-site based information and more recently through the use of smart phone based applications. such educational campaigns have financial implications for hospitals and institutions. the level of knowledge among patients with vascular disease of their pathology and its associated risk factors has been shown to be poor (lovell et al 2009, hirsch et al 2007). the optimum tool with which to provide information to patients with vascular disease has not been determined to date.

Eligibility criteria:
inclusion criteria: * newly diagnosed abdominal aortic aneurysm, peripheral vascular disease or varicose veins * capacity to and willingness to consent to participation in the study * adult patients * in-patient or out-patient status exclusion criteria: * previously diagnosed with vascular disease * limited capacity or unwilling to consent * information already provided by hospital doctor * cognitive/intellectual impairment/acquired brain injury/visual impairment * qualified medical professionals

Keywords: patient information vascular disease abdominal aortic aneurysm varicose veins web based information
a comparison of sample collection methods for sars-cov-2 antibody testing

Conditions: COVID-19

Summary: the negative global consequences of the covid-19 pandemic has prompted efforts to develop efficient laboratory testing protocols that can be quickly scaled in a practical way. traditional phlebotomy requirements for antibody testing (venipuncture) often serve as a barrier to widespread population testing since they typically require dedicated facilities and personnel training. conversely, antibodies are typically very stable in blood and require very little testing volume, which make antibody tests well suited to be run on samples collected via finger-stick, saliva, or other self-administered collection devices. salveo diagnostics is a clia/cap certified clinical laboratory that routinely performs testing for anti-sars-cov-2 antibodies. the purposes of this protocol are to 1) assess the feasibility of streamlined sample collection procedures for assessing covid-related immune status, and 2) to provide a mechanism for securing sequential samples in covid positive and negative patients to support additional studies (e.g. investigating timing of anti-sars-cov-2 antibody class switching and antibody persistence).


Eligibility criteria:
inclusion criteria: * confirmed presence (n = 200) or absence (n = 100) of anti-sars-cov2 antibodies * \>17 years old exclusion criteria: * refusal or inability to provide informed consent
olmesartan in essential hypertension

Conditions: Essential Hypertension

Summary: to test the efficacy and safety of olmesartan in patients with essential hypertension.


Eligibility criteria:
inclusion criteria: * age: 18 (19 if required by local authorities) to 75 years * males and females of any race. female participants must take adequate contraceptive measures (oral contraceptives, i.u.d.), be post-menopausal or surgically sterilized * essential hypertension: sitting dbp greater than or equal to 90 and less than 110 mmhg * written informed consent * mentally competent * negative pregnancy test in women at a childbearing age at the beginning of the study exclusion criteria: * patients with known severe (world health organization (who) stage iii, sitting dbp stable at greater than or equal to 110 mmhg), malignant or secondary hypertension * patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty (ptca) or coronary artery bypass graft (cabg) within the last 6 months * patients with a history or current evidence of congestive heart failure * bilateral renal artery stenosis * severe renal insufficiency (serum creatinine greater than 200 micro mol/l) * severe hepatic impairment or biliary obstruction
circulating tumor dna guided therapeutic strategies for crc patients with small pulmonary nodules

Conditions: Advanced Colorectal Cancer; Circulating Tumor DNA

Summary: the clinical diagnosis and treatment of small pulmonary nodules (suspected to be lung metastases) in advanced colorectal cancer patients remain controversy. previous studies have shown that tumor-informed circulating tumor dna (ctdna) blood testing can sensitively detect residual cancer. postoperative ctdna in colorectal cancer patients is a valuable biomarker to identify minimal residual disease (mrd) after radical resection, which is possibly useful in redefining the risk group of patients and guiding postoperative treatment. this study aimed to explore the clinical value of therapeutic strategies based on tumor-informed ctdna test in advanved colorectal cancer patients with small pulmonary nodules.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤80 years old, regardless of gender; 2. pathologically confirmed as adenocarcinoma of advanced colorectal cancer; 3. lung lesions only, which was considered as metastatic by imaging consultation, and clinically diagnosed as lung metastasis of colorectal cancer; 4. multiple lung lesions are allowed, but the maximum lesion diameter should be less than or equal to 2 cm; 5. for lesions larger than 1 cm, local treatment is planned, such as radical surgical resection or local radiotherapy, radio frequency ablation or interventional therapy (absolute alcohol treatment or cryotherapy); 6. eastern cooperative oncology group (ecog) score 1 \~ 2; 7. the subjects (or their legal representative / guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study; 8. surgical specimens or puncture specimens containing tumor tissue are available; 9. 20 ml of peripheral blood are available (10 ml per tube, two tubes in total); 10. agreed to follow up for at least 2 years. exclusion criteria: 1. the pathology was not confirmed by enteroscopic biopsy or biopsy of metastatic lesions; 2. patients with stage i-iii colorectal cancer; 3. primary lung cancer, ggo, tuberculosis and other non metastatic conditions were excluded after diagnosis by imaging consultation; 4. presence of metastasis other than lung; 5. insufficient organ function, such as severe abnormal hemogram, abnormal liver and kidney function; 6. any signs of severe or uncontrolled systemic diseases that the researcher believes may have a significant patient risk/benefit balance, including uncontrolled hypertension, severe infection, hepatitis b, hepatitis c and human immunodeficiency virus; 7. history of alcoholism or drug abuse; 8. pregnant or lactating patients.

Keywords: advanced colorectal cancer lung metastasis circulating tumor dna
efficacy and safety study of electroacupuncture for simple female stress urinary incontinence-a multicenter trial

Conditions: Urinary Stress Incontinence

Summary: the purpose of this study is to evaluate the efficacy and safety of electroacupuncture （ea） for simple female stress urinary incontinence.

stress urinary incontinence (sui) is a common disease of female. the inconvenience caused by sui affects the patients' quality of life and health seriously. to date, there has not specific therapy on sui. former research showed acupuncture may work for sui. this multi-center randomized controlled clinical trial of acupuncture for simple female stress urinary incontinence is designed to confirm the efficacy and safety of ea. this project is conducted by chinese researchers, supported by the chinese government. the research result is expected to provide high quality evidence of ea for simple female stress urinary incontinence.

Eligibility criteria:
inclusion criteria: * meet the diagnosis of simple female stress urinary incontinence * 40-75 years old * volunteered to join this research and signed the informed consent exclusion criteria: * urge urinary incontinence, mixed urinary incontinence, overflow urinary incontinence, etc * after operation for urinary incontinence or pelvic floor operation * edeoptosis≥degree 2 * symptomatic urinary tract infection * ruv\>30ml * qmax\<20ml/s * constrained movement of walking, stairs climbing, running * patients with continuous treatment for stress urinary incontinence or medicine for bladder function * with serious cardiovascular, cerebral, liver, kidney, or psychiatric disease, diabetes, msa, injury of cauda equine, myeleterosis. * during pregnancy or lactation period * with cardiac pacemaker, metal allergy or severe needle phobia

Keywords: efficacy safety electroacupuncture simple female stress urinary incontinence
impact of tamsulosin on post-operative urinary retention following pelvic reconstructive surgery

Conditions: Urinary Retention Postoperative

Summary: the objective of the study is to determine the effectiveness of postoperative tamsulosin in reducing the duration of acute postoperative urinary retention (pour) following pelvic reconstructive surgery through a double blind, randomized placebo-controlled trial.

the primary objective is to determine the impact of tamsulosin on duration of urinary retention following pelvic reconstructive surgery in women. duration of catheterization via indwelling foley or clean intermittent self-catheterization (cisc), measured in days, will be compared between women receiving tamsulosin versus placebo after diagnosis of postoperative urinary retention via standardized voiding trial. it is hypothesized that women receiving tamsulosin will have a shorter duration of urinary retention, fewer urinary tract infections, and improved quality of life as compared with placebo. the euroqol-5d (eq-5d) will be used to compare physical, emotional, functional, and social/family well-being between women receiving tamsulosin and placebo. upon diagnosis of pour, women will be offered participation in the study. once consent is obtained, women will be randomized to tamsulosin 0.4 mg or matching placebo capsules to be used daily until resolution of pour or a 10 day course, whichever occurs first.

Eligibility criteria:
inclusion criteria: * 18 years or older * willing and able to provide informed consent * postoperative urinary retention as defined by a failed rgvt prior to hospital discharge * ability to speak and read english * tolerate pill ingestion exclusion criteria: * allergy/intolerance to tamsulosin or sulfa drugs * preoperative history of urinary retention as defined by preoperative post void residual of \>150ml * current use of alpha antagonist medication for hypertension * severe dementia * end stage renal or liver disease * history of severe heart failure or major cardiovascular event in the last 6 months
once-daily oral direct factor xa inhibitor bay59-7939 in patients with acute symptomatic deep-vein thrombosis

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to determine the optimal dose of bay 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin k antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.

within the u.s., johnson \& johnson is sponsor.

Eligibility criteria:
inclusion criteria: * confirmed acute symptomatic dvt, i.e. proximal or extensive calf-vein thrombosis involving at least the upper third part of the calf veins, without concomitant symptomatic pe * written informed consent exclusion criteria: * legal lower age limitations (country specific) * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of dvt * other indication for vka than pe/dvt * more than 36 hours pre-randomization treatment with therapeutic dosages of (lmw) heparin or more than a single dose of vka prior to randomization * participation in another pharmacotherapeutic study within the prior 30 days * creatinine clearance \ 2 x uln), or bacterial endocarditis * life expectancy \< 3 months * active bleeding or high risk for bleeding contraindicating treatment with (lmw) heparin * uncontrolled hypertension: systolic blood pressure \> 200 mmhg and diastolic blood pressure \> 110 mmhg * pregnancy or childbearing potential without proper contraceptive measures * any other contraindication listed in the labeling of warfarin, acenocoumarol, phenprocoumon, fluindione, ufh, enoxaparin, or tinzaparin * systemic treatment with azole compounds or other strong cyp3a4 inhibitors (e.g. ketoconazole, fluconazol, itraconazole, hiv protease inhibitors) within 4 days prior to randomization and during the study

Keywords: treatment of venous thromboembolism
evaluation of factors that cause secondary brain damage on mortality and morbidity in patients undergoing emergency surgery due to head trauma.

Conditions: Brain Injuries

Summary: traumatic brain injury is combination damage that occurs as a result of a chain reaction of various metabolic events that develop after primary damage caused by trauma. pathological events such as lactic acidosis, electrolyte imbalance, increased inflammation that occur during traumatic brain injury leads to poor prognosis in patients. the retrospective study was conducted to investigate the effect of factors that may cause secondary damage, especially electrolyte imbalance and blood glucose levels, on mortality and morbidity in patients undergoing emergency surgery due to head trauma.


Eligibility criteria:
inclusion criteria: * patients who admitted to bursa uludag university hospital between 2013 and 2018 * patients diagnosed with traumatic brain injury and operated within the first 24 hours after admission exclusion criteria: * pediatric patients * patients that operated after 24 hour of admission

Keywords: secondary brain damage electrolyte imbalance head trauma
improving the sleep of cancer patients using an internet-based program

Conditions: Cancer; Insomnia

Summary: the purpose of this study is to determine whether an internet-based program, sleep healthy using the internet (shuti, or "shut-eye"), can help to improve the sleep of people who are in remission from cancer and experiencing symptoms of insomnia.

the purpose of this study is to test the feasibility of using an internet program to improve the sleep of cancer patients with insomnia. participants will receive access to the internet program (called shuti, or "shut-eye") as well as to self-hypnosis recordings designed to improve sleep. shuti provides an online, tailored educational program to individuals who are experiencing sleep difficulties, including those having difficulty falling asleep, waking in the middle of the night, and waking too early in the morning.

Eligibility criteria:
inclusion criteria: * age = at least 21 years old * regular access to the internet, including e-mail * cancer patient * any type of cancer (except non-melanoma skin cancer) * in remission from any stage of cancer (active treatment completed at least one month prior to enrollment) * insomnia diagnosis (combined from dsm-iv and icsd): * subjective complaints of poor sleep for at least 6 months * sleep difficulties ≥3 nights/week * difficulty falling asleep (≥30 minutes to fall asleep) or * difficulty staying asleep (≥30 minutes awake in the middle of the night) * ≤6.5 hours sleep/night * poor sleep causes marked distress or significant impairment in daytime functioning (e.g. fatigue, performance deficits, mood disturbance) * participant feels that the insomnia was caused/aggravated by cancer or cancer treatment exclusion criteria: * having a sleep disorder other than insomnia (e.g. sleep apnea, rls, narcolepsy, parasomnias) * having a medical condition other than cancer that causes insomnia * experiencing a psychiatric disturbance (major depression, psychosis) * experiencing substance abuse * currently undergoing psychotherapy or counseling * changing sleep/anxiety/depression medication within the past month * having an "unusual" sleep pattern * normal bedtime is after 2am or * normal wake time is after 9am * working as a shift worker (that is, having a schedule that requires working through the night) * participants reports that she is pregnant or intending to get pregnant in the next 4 months

Keywords: cancer sleep insomnia internet shuti
tofacitinib (xeljanz) special investigation for rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of this surveillance is to verify the following subject matters concerning tofacitinib (xeljanz) under general practice. 1) occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） long-term safety (particularly, malignant tumors and serious infections) and efficacy occurrences of malignant tumors and serious infections will be compared with a control group.

all the patients whom an investigator prescribes the xeljanz or standard of care for rheumatoid arthritis should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * all patients receiving tofacitinib (xeljanz) exclusion criteria: not applicable

Keywords: rheumatoid arthritis good post marketing study practice tofacitinib xeljanz regulatory post marketing commitment plan
design and application of vitamin d films for burn healing after cauterizing surgery

Conditions: Nasal Obstruction

Summary: one of this method's drawbacks is the healing of cauterized cartilage after processing. it was reported that the healing is so slow as no dosage form can reach this place in addition to the scares produced from healing is very irritable to the patient. from this point, the investigators start searching for a solution to this problem and reach the repositioning of vitamin d3 (calciferol) as an active ingredient for the rapidity and efficacy of burn healing. the dosage form of choice that was reported before for intranasal application by the same team of investigators and gave good results. the intranasal films were proved for its convince, simplicity, efficacy, and compliance to patients.


Eligibility criteria:
inclusion criteria: * patients complain of nasal obstruction * do not respond to medications * treatment need surgery * patients accept following up in a timely manner for 3 weeks exclusion criteria: * no nasal polyps, * have problems with the surgical procedures * have allergy with any of the treatment components (vitamin d3 or chitosan) * don't follow instructions or miss the following up
digital biomarkers for the assessment of motor status in parkinson's disease patients with clinical and therapeutic application

Conditions: Parkinson Disease; Parkinson

Summary: the goal of this observational study is to define digital biomarkers of motor symptoms in parkinson's disease patients using wearable devices. the main questions it aims to answer is: * is there a biomarkers that allows the identification of pd from healthy controls? * is there a biomarkers that can identify the severity of the disease? * is there a biomarkers with clinical and therapeutic application that can be used in clinical and free living conditions to monitor the evolution of the disease? participants have to perform a set of guided exercises related to the mds-updrs guide and daily living tasks, in supervised and unsupervised conditions.

the participants must perform a set of exercises related to the mds-updrs iii scale and some free-living activities. these tasks must be performed wearing a smartwatch. the activities will be done in supervised clinical and unsupervised free-living environments. the participants must perfom a baseline and a final assesment in supervised conditions and a week of free living monitoring.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease based on the uk brain bank criteria. * affiliated with asociación parkinson madrid. * minimal or mild disease severity, defined by a hoehn and yahr scale score of ≤ 2.5. * be capable of performing the prescribed exercises independently. * maintain daily functioning without dependence on caregivers. exclusion criteria: * hoehn and yahr scale score of \> 2.5. * have undergone deep brain stimulation, used dopamine infusion pumps, or have conditions mimicking pd symptoms (e.g., progressive supranuclear palsy, lewy body dementia, multiple system atrophy, or other parkinsonian syndromes) * experience motor symptom fluctuations throughout the day.

Keywords: parkinson biomarkers home monitoring wearable smartwatch